Verismo Therapeutics SynKIR-110 Shows Promising Safety Profile in Phase 1 STAR-101 Trial for Advanced Solid Tumors

Key Takeaways

• SynKIR-110 showed favorable safety profile with no dose-limiting toxicities across initial dose cohorts in advanced solid tumor patients
• Preliminary data indicate dose-dependent efficacy signals and increased cell persistence at higher dose levels
• Dose escalation continues in the STAR-101 Phase 1 trial to determine recommended Phase 2 dose

---

Verismo Therapeutics announced promising initial clinical data from its STAR-101 Phase 1 trial of SynKIR-110, a novel KIR-CAR therapy for advanced solid tumors, presented at the AACR 2026 Plenary Session on April 20, 2026.

The early clinical results demonstrate a favorable safety profile across the first three dose level cohorts, with no dose-limiting toxicities observed. This milestone allows the company to continue dose escalation to determine the optimal Phase 2 dose for this potentially first-in-class multi-chain KIR-CAR living medicine.

Clinical Results Show Promise

Preliminary data from the STAR-101 trial revealed dose-dependent efficacy signals, suggesting that higher doses of SynKIR-110 may provide enhanced therapeutic benefit. The therapy also demonstrated on-tumor target biologic activity with increased cell persistence at elevated dose levels, indicating the treatment’s ability to maintain therapeutic presence where needed.

SynKIR-110 represents a novel approach to cancer immunotherapy, utilizing KIR-CAR (Killer Immunoglobulin-like Receptor Chimeric Antigen Receptor) technology to potentially overcome limitations of traditional CAR-T therapies in solid tumors.

IntelligenceRegulatory Impact▾

FDA are the agencies to watch. Regulatory relevance reads medium for pharmaceutical intelligence. Teams should track submission types, designations, and guidance shifts that could move approval timelines.

Market Implications

The positive safety profile and early efficacy signals position Verismo Therapeutics competitively in the expanding CAR-T therapy market, particularly for solid tumors where treatment options remain limited. The company’s multi-chain KIR-CAR platform could differentiate it from existing immunotherapies.

IntelligenceCompetitive Intelligence▾

Competitive pressure is low. Watch which sponsors move first. Benchmark pipeline positioning, differentiation, and partnership scouting against the signals in this story.

Next Steps

Verismo plans to continue dose escalation in the ongoing Phase 1 trial to establish the recommended Phase 2 dose. The company will likely provide updated data at future medical conferences as enrollment progresses and more patients reach evaluable timepoints.

The STAR-101 trial’s progression without dose-limiting toxicities represents a significant milestone for both Verismo and patients with advanced solid tumors who have limited treatment options.

---

Frequently Asked Questions

What does this mean for patients with advanced solid tumors?

The positive safety data and early efficacy signals suggest SynKIR-110 could become a new treatment option for patients with advanced solid tumors, though the therapy is still in early-stage testing and not yet available outside clinical trials.

When will SynKIR-110 be available to patients?

SynKIR-110 is currently in Phase 1 trials. If successful, it would need to complete Phase 2 and Phase 3 trials before potential FDA approval, which typically takes several years.

How does SynKIR-110 differ from existing CAR-T therapies?

SynKIR-110 uses multi-chain KIR-CAR technology designed specifically for solid tumors, potentially overcoming challenges that traditional CAR-T therapies face in treating solid cancers compared to blood cancers.

Related coverage

• BioNTech doses first patient in Phase 1 pancreatic cancer mRNA vaccine trial
• Moderna's mRNA-1083 Phase 3 shows stronger flu and COVID immune responses
• Lenacapavir PrEP shows high HIV-prevention efficacy in Gilead’s Phase 3 trials